153 related articles for article (PubMed ID: 35773149)
21. Reply to Binghao Zhao, Hao Xing, and Wenbin Ma's Letter to the Editor re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116.
Ernst MS; Heng DYC
Eur Urol; 2023 Jul; 84(1):e18-e19. PubMed ID: 37080894
[No Abstract] [Full Text] [Related]
22. Reply to Yongbao Wei, Haijian Huang, and Liefu Ye's Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469-82.
Rubin MA; Amin MB; Compérat E; Gill A; Hartman A; Menon S; Raspollini M; Srigley J; Tan PH; Ticktoo S; Tsuzuki T; Turajlic S; Cree I; Berney D; Moch H; Netto GJ
Eur Urol; 2023 Jan; 83(1):e16-e17. PubMed ID: 36202688
[No Abstract] [Full Text] [Related]
23. Reply to Anju Murayama's Letter to the Editor re: David-Dan Nguyen, Liam Murad, Anne Xuan-Lan Nguyen, et al. Industry Payments to American Editorial Board Members of Major Urology Journals. Eur Urol. Eur Urol. 2023;84:442-43.
Nguyen DD; Nguyen AV; Murad L; Labban M; Trinh QD; Wallis CJD; Bhojani N
Eur Urol; 2023 Dec; 84(6):e140-e141. PubMed ID: 37770285
[No Abstract] [Full Text] [Related]
24. Re: Paul C.M.S. Verhagen, Egbert R. Boevé. The European Association of Urology Guideline on Renal Cell Carcinoma (RCC) is Not Concise in its Recommendation to Perform Partial Nephrectomy in T1b RCC. Eur Urol 2019:76:136-7.
Marconi L; Bensalah K; Bex A;
Eur Urol; 2019 Jul; 76(1):e12-e13. PubMed ID: 30922689
[No Abstract] [Full Text] [Related]
25. Reply to Rui-Cheng Wu, Deng-Xiong Li, and De-Chao Feng's Letter to the Editor re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. 2024;85:146-53.
Eppler M; Ganjavi C; Abreu A; Gill I; Cacciamani GE
Eur Urol; 2024 Mar; 85(3):e85-e86. PubMed ID: 38182492
[No Abstract] [Full Text] [Related]
26. Reply to Brett Delahunt, Hemamali Samaratunga, Lars Egevad's Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31. Should Chromophobe Renal Cell Carcinoma Be Graded?
Avulova S; Cheville JC; Lohse CM; Potretzke AM
Eur Urol; 2021 May; 79(5):e143-e144. PubMed ID: 33637366
[No Abstract] [Full Text] [Related]
27. Reply to Riccardo Bertolo's Letter to the Editor re: Giorgio Gandaglia, Carlo Andrea Bravi, Paolo Dell'Oglio, et al. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. Eur Urol 2018;74:4-7.
Gandaglia G; Fossati N; Montorsi F; Briganti A
Eur Urol; 2018 Nov; 74(5):e116-e117. PubMed ID: 30007820
[No Abstract] [Full Text] [Related]
28. Reply to Qingpeng Xie and Dianqiu Shen's Letter to the Editor re: Bhavan P. Rai, José Luis Dominguez Escrig, Luís Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182-92.
Prasad Rai B; Violette PD; Imran Omar M
Eur Urol; 2024 Jan; 85(1):e15-e16. PubMed ID: 37833174
[No Abstract] [Full Text] [Related]
29. Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8.
Davis ID; Pezaro C; Xie W; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):e177-e178. PubMed ID: 28041718
[No Abstract] [Full Text] [Related]
30. Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766-72: Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Takahashi T
Eur Urol; 2019 Sep; 76(3):e65-e66. PubMed ID: 31164251
[No Abstract] [Full Text] [Related]
31. Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
van der Poel HG; van den Bergh RCN; Briers E; Cornford P; Govorov A; Henry AM; Lam TB; Mason MD; Rouvière O; De Santis M; Wiegel T; Willemse PM; van Poppel H; Mottet N
Eur Urol; 2019 Feb; 75(2):e23-e24. PubMed ID: 30237024
[No Abstract] [Full Text] [Related]
32. Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73.
Marconi L; Lam TB; Bex A; Ljungberg B; Volpe A
Eur Urol; 2016 Jun; 69(6):e119-20. PubMed ID: 26776936
[No Abstract] [Full Text] [Related]
33. Reply to Pascal Mouracade's letter to the editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9.
Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
Eur Urol; 2015 Oct; 68(4):e84-5. PubMed ID: 26058957
[No Abstract] [Full Text] [Related]
34. Reply to Juan Pablo Valdevenito, Marcio Augusto Averbeck, Sanjay Sinha, Enrico Finazzi-Agro, and Andrew Gammie's Letter to the Editor re: Karl H. Pang, Riccardo Campi, Salvador Arlandis, et al. Diagnostic Tests for Female Bladder Outlet Obstruction: A Systematic Review from the European Association of Urology Non-neurogenic Female LUTS Guidelines Panel. Eur Urol Focus 2022;8:1015-30.
Pang KH; Campi R; Imran Omar M; Harding CK
Eur Urol Focus; 2023 Jul; 9(4):629-630. PubMed ID: 36737363
[No Abstract] [Full Text] [Related]
35. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma.
Santoni M; Montironi R; Battelli N; Massari F
Eur Urol; 2019 Mar; 75(3):e64-e66. PubMed ID: 30391082
[No Abstract] [Full Text] [Related]
36. Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14.
Hsieh JJ; Marker M; Chen D
Eur Urol; 2017 Sep; 72(3):e74-e75. PubMed ID: 28111113
[No Abstract] [Full Text] [Related]
37. Reply to Homayoun Zargar, Rafael F. Coelho and Jihad H. Kaouk's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9.
Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
Eur Urol; 2015 Feb; 67(2):e24-5. PubMed ID: 25257032
[No Abstract] [Full Text] [Related]
38. Reply to Aaron M. Potretzke, Jeffrey A. Larson and Sam B. Bhayani's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9.
Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
Eur Urol; 2015 Feb; 67(2):e21-2. PubMed ID: 25257031
[No Abstract] [Full Text] [Related]
39. Re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol. 2021;80:760-2: Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki.
Takahashi T
Eur Urol; 2022 Feb; 81(2):e44-e45. PubMed ID: 34887116
[No Abstract] [Full Text] [Related]
40. Reply to Marc Bjurlin, Elena Elkin, and William Huang's Letter to the Editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol 2014;65:235-41.
Sun M; Karakiewicz PI
Eur Urol; 2015 Apr; 67(4):e72. PubMed ID: 25179937
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
